=== PAGE 4 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its layout and structure:

Jenny McNeil
Exeltis USA Inc.
NDA 211367/ MA 40

                                                                                                       Page 4

Please direct your response to the undersigned at the **Food and Drug Administration,
Center for Drug Evaluation and Research, Office of Prescription Drug Promotion**, **5901-
B Ammendale Road, Beltsville, Maryland 20705-1266**. A courtesy copy can be sent by
facsimile to (301) 847-8444. Please refer to MA 40 in addition to the NDA number in all future
correspondence relating to this particular matter. All correspondence should include a subject
line that clearly identifies the submission as a Response to Untitled Letter. You are
encouraged, but not required, to submit your response in eCTD format. All correspondence
submitted in response to this letter should be placed under eCTD Heading 1.15.1.6.
Questions related to the submission of your response letter should be emailed to the OPDP
RPM at CDER-OPDP-RPM@fda.hhs.gov.


                                                                   Sincerely,

                                                                   {See appended electronic signature page}

                                                                   Elvy Varghese, PharmD.
                                                                   Regulatory Review Officer
                                                                   Division of Advertising & Promotion Review 2
                                                                   Office of Prescription Drug Promotion

                                                                   James Dvorsky, PharmD., MPH
                                                                   Team Leader
                                                                   Division of Advertising & Promotion Review 2
                                                                   Office of Prescription Drug Promotion



Reference ID: 5225246
